Adalimumab/infliximabMelanoma: 4 case reports

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2016年 / 1624卷 / 1期

关键词：

D O I：

10.1007/s40278-016-22224-9

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：18 / 18

相关论文

共 50 条

[1] Adalimumab/infliximabTuberculosis: 4 case reports
Reactions Weekly, 2014, 1532 (1) : 17 - 17
[2] Adalimumab/infliximabPsoriasis: 4 case reports
Reactions Weekly, 2008, 1198 (1) : 4 - 5
[3] Adalimumab/etanerceptDermatomyositis?: 4 case reports
Reactions Weekly, 2010, 1317 (1) : 9 - 9
[4] Adalimumab/etanerceptMultiple sclerosis: 4 case reports
Reactions Weekly, 2011, 1350 (1) : 8 - 8
[5] Adalimumab/InfliximabLack of efficacy: 4 case reports
Reactions Weekly, 2024, 2027 (1) : 21 - 21
[6] Adalimumab/bucillamineMembranous nephropathy: 4 case reports
Reactions Weekly, 2023, 1960 (1) : 18 - 18
[7] Adalimumab/infliximabMiliary tuberculosis: 4 case reports
Reactions Weekly, 2015, 1551 (1) : 15 - 15
[8] Adalimumab/infliximabVarious toxicities: 4 case reports
Reactions Weekly, 2018, 1731 (1) : 16 - 16
[9] Adalimumab/infliximabDemyelinating disease: 4 case reports
Reactions Weekly, 2019, 1752 (1) : 17 - 17
[10] Adalimumab/etanerceptOptic neuritis: 4 case reports
Reactions Weekly, 2013, 1439 (1) : 5 - 5

← 1 2 3 4 5 →